Genome-wide screening of loci associated with drug resistance to 5-fluorouracil-based drugs

Cancer Science

Volumn 98, Issue 4, 2007, Pages 577-583

  Ooyama, Akio ^a   Okayama, Yoshihiro ^a   Takechi, Teiji ^a   Sugimoto, Yoshikazu ^a   Oka, Toshinori ^a   Fukushima, Masakazu ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BETA ACTIN; CAPECITABINE; DNA; DOXIFLURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; RNA; THYMIDYLATE SYNTHASE; UFT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER MORTALITY; CANCER PATIENT; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME 18P; CHROMOSOME ABERRATION; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DNA DETERMINATION; DRUG RESPONSE; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CARCINOMA; TUMOR VOLUME; TUMOR XENOGRAFT;

ALGORITHMS; ANIMALS; CHROMOSOME ABERRATIONS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEASIBILITY STUDIES; FLUOROURACIL; GENE DOSAGE; GENETIC TECHNIQUES; HUMANS; MICE; MICE, NUDE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 34147190058     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00424.x     Document Type: Article

References (37)

1. Ross DT, Scherf U, Eisen MBC et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24: 227-35.
2. Scherf U, Ross DT, Waltham M et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24: 236-44.
3. Staunton JE, Slonim DK, Coller HA et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001; 98: 10 787-92.
4. Zembutsu H, Ohnishi Y, Tsunoda T et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 2002; 62: 518-27.
5. Dan S, Tsunoda T, Kitahara O et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002; 62: 1139-47.
6. Takechi T, Okabe H, Ikeda K et al. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts. Oncol Report 2005; 14: 33-9.
7. Ooyama A, Takechi T, Toda E et al. Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci 2006; 97: 510-22.
8. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review. Oncologist 2002; 7: 288-323.
9. Fukushima M, Shimamoto Y, Kato T et al. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs 1998; 9: 817-23.
10. Langenbach RJ, Danenberg PV, Heidelberger C. Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 1972; 6: 1565-71.
11. Takechi T, Koizumi K, Tsujimoto H, Fukushima M. Screening of differentially expressed genes in 5-fluorouracil-resistant human gastrointestinal tumor cells. Jpn J Cancer Res 2001; 92: 696-703.
12. Charames GS, Bapat B. Genomic instability and cancer. Curr Mol Med 2003; 3: 589-96.
13. Kallioniemi A, Kallioniemi OP, Sudar D et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818-21.
14. Gaasenbeek M, Howarth K, Rowan AJ et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers. Cancer Res 2006; 7: 3471-9.
15. Janne PA, Li C, Zhao X et al. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene 2004; 15: 2716-26.
16. Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 2001; 37: 1681-7.
17. Nukatsuka M, Fujioka A, Nakagawa F et al. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. Int J Oncol 2004; 25: 1531-6.
18. Takechi T, Okabe H, Ikeda K et al. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts. Oncol Rep 2005; 14: 33-9.
19. UKCCCR Guidelines. United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (2nd edn). Br J Cancer 1998; 77: 1-10.
20. Zhao X, Li C, Paez JG et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004; 64: 3060-71.
21. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD. Searching expressed sequence tag databases: Discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000; 9: 1381-5.
22. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982; 42: 450-6.
23. Mitra AB, Murty VV, Pratap M, Sodhani P, Chaganti RS. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 1994; 54: 637-9.
24. Escot C, Theillet C, Lidereau R et al. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 1986; 83: 4834-8.
25. Cairns P, Polascik TJ, Eby Y et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995; 11: 210-12.
26. Hidaka S, Yasutake T, Fukushima M et al. Chromosomal imbalances associated with acquired resistance to fluoropyrimidines in human colorectal cancer cells. Eur J Cancer 2003; 39: 975-80.
27. Wang W, Marsh S, Cassidy J, McLeod HL. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res 2001; 61: 5505-10.
28. Wang TL, Diaz LA Jr, Romans K et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 2004; 101: 3089-94.
29. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-12.
30. Lenz HJ, Hayashi K, Salonga D et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin Cancer Res 1998; 4: 1243-50.
31. Brody JR, Hucl T, Gallmeier E, Winter JM, Kern SE, Murphy KM. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: A model for patient classification to aid fluoropyrimidine therapy. Cancer Res 2006; 19: 9369-73.
32. Wotton D, Lo RS, Lee S, Massague J. A Smad transcriptional corepressor. Cell 1999; 1: 29-39.
33. Raynal S, Nocentini S, Croisy A, Lawrence DA, Jullien P. Transforming growth factor-β1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Int J Cancer 1997; 2: 356-61.
34. Alhopuro P, Alazzouzi H, Sammalkorpi H et al. SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res 2005; 17: 6311-16.
35. Muramatsu T. Midkine and pleiotrophin: Two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem (Tokyo) 2002; 3: 359-71.
36. Kang HC, Kim IJ, Park JH et al. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 2004; 10: 272-84.
37. Kang HC, Kim IJ, Park JH et al. Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance. Cancer Lett 2007; 1: 40-7.